Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich
Wockhardt shares surged nearly 27% in two days after the US FDA accepted its New Drug Application for the antibiotic Zaynich, marking a first for an Indian pharma company. Trading volumes on the NSE soared 34 times above average Monday, with the stock hitting ₹1,566 intraday Tuesday. The stock had been largely flat in 2025 before the rally.
